Physiol. Genomics Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 26: 192-201, 2006. First published May 9, 2006; doi:10.1152/physiolgenomics.00196.2005 Free Article
1094-8341/06 $8.00
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrowFree Article All Versions of this Article:
26/3/192    most recent
00196.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willsky, G. R.
Right arrow Articles by Crans, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willsky, G. R.
Right arrow Articles by Crans, D. C.
Received 5 August 2005; accepted in final form 4 May 2006.
Physiological Genomics 26:192-201 (2006)
1094-8341/06 $8.00 © 2006 American Physiological Society

Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate

Gail R. Willsky1, Lai-Har Chi1, Yulan Liang2, Daniel P. Gaile2, Zihua Hu3 and Debbie C. Crans4

1 Department of Biochemistry, School of Medicine and Biomedical Sciences, The State University of New York (SUNY) at Buffalo, Buffalo
2 Department of Biostatistics, School of Public Health and Health Professions, SUNY at Buffalo, Buffalo
3 Center for Computational Research, Department of Biostatistics, Department of Medicine, SUNY at Buffalo, Buffalo, New York
4 Department of Chemistry, Colorado State University, Fort Collins, Colorado

Treatment with vanadium, a representative of a class of antidiabetic compounds, alleviates diabetic hyperglycemia and hyperlipidemia. Oral administration of vanadium compounds in animal models and humans does not cause clinical symptoms of hypoglycemia, a common problem for diabetic patients with insulin treatment. Gene expression, using Affymetrix arrays, was examined in muscle from streptozotocin-induced diabetic and normal rats in the presence or absence of oral vanadyl sulfate treatment. This treatment affected normal rats differently from diabetic rats, as demonstrated by two-way ANOVA of the full array data. Diabetes altered the expression of 133 genes, and the expression of 30% of these genes dysregulated in diabetes was normalized by vanadyl sulfate treatment. For those genes, the ratio of expression in normal animals to the expression in diabetic animals showed a strong negative correlation with the ratio of expression in diabetic animals to the expression in diabetic animals treated with vanadyl sulfate (P = –0.85). The genes identified belong to six major metabolic functional groups: lipid metabolism, oxidative stress, muscle structure, protein breakdown and biosynthesis, the complement system, and signal transduction. The identification of oxidative stress genes, coupled with the known oxidative chemistry of vanadium, implicates reactive oxygen species in the action of this class of compounds. These results imply that early transition metals or compounds formed from their chemical interactions with other metabolites may act as general transcription modulators, a role not usually associated with this class of compounds.

vanadium; microarray; streptozotocin







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.